Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Nemo-like kinase (NLK) is an evolutionarily conserved serine/threonine kinase implicated in various cancers.
• Understanding NLK's role in non-small-cell lung cancer (NSCLC) is crucial for therapeutic development.

Purpose of the Study:

• To investigate the expression and prognostic significance of NLK in NSCLC.
• To elucidate the functional role of NLK in NSCLC cell proliferation and its underlying molecular mechanisms.

Main Methods:

• Western blot analysis of NLK expression in paired NSCLC tissues and cell lines.
• Immunohistochemistry (IHC) on 83 NSCLC paraffin-embedded slices.
• In vitro studies using NSCLC cell line A549, including serum starvation, RNA interference (RNAi) for NLK knockdown, Western blot, flow cytometry, and assessment of β-catenin/TCF transcription activity.

Main Results:

• NLK was found to be lowly expressed in NSCLC tissues and significantly associated with differentiation, clinical stage, lymph node status, and Ki-67 expression.
• Low NLK expression served as an independent prognostic factor for reduced survival rates in NSCLC patients.
• NLK knockdown in NSCLC cells led to increased proliferation, cell cycle progression (S-phase and mitosis), and enhanced β-catenin/TCF transcription activity, indicating modulation of the Wnt signaling pathway.

Conclusions:

• NLK plays a suppressive role in NSCLC cell proliferation.
• The findings suggest that NLK downregulation promotes NSCLC progression via cell cycle dysregulation and Wnt pathway activation.
• NLK represents a potential therapeutic target for NSCLC treatment.